Lastly, previous work has not included study of pre-existing autoantibodies to IFN, which studies have shown to be associated with poor outcomes after COVID-19, or the effect of genetic variation in innate immunity genes, which could be associated with differential responses to IFN-pathway drugs [14]. The gene discussed is IFNA1; the disease is COVID-19.